Long-term follow-up study for CAR T-cell therapy patients
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study follows children and young adults who received CAR T-cell therapy for B-cell ALL at least two years ago. It checks long-term side effects, how well the therapy worked over time, and quality of life, so doctors can better understand the lasting impacts of CAR T-cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were 26 or younger when you got CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL).
- The CAR T-cells targeted a protein called CD19.
- You received only one unique kind of CAR product (reinfusion of the same one is okay).
- You have been in remission for at least 2 years since your last CAR T-cell infusion, with no additional cancer treatments except possibly a stem cell transplant.
- You had no more than one stem cell transplant at any time (before or after CAR).
- You are willing and able to give written consent (or have a legal guardian do it).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children and young adults who received CAR T cell therapy to understand any long-term side effects that may appear months to years later. By joining, you help researchers learn how to better care for patients after this treatment.
This trial tests whether giving two types of CAR T cells (CD19 and CD22) one after the other works better than giving just one type (CD19) followed by a stem cell transplant for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or not gone away. The goal is to see which approach offers a better chance of long-term remission.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This study checks how people do over the long run after receiving a personalized, genetically modified CAR T cell treatment. It may help researchers understand long-term safety and outcomes, which can improve future care.
This study looks at why CAR T-cell therapy stops working in some children and young adults with leukemia. It aims to help doctors understand how to make this treatment last longer.
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
Hear when a new B-Cell Acute Lymphoblastic Leukemia (B-ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.